Real World Research Big Data Opens a New Chapter in Chronic Disease Management – The First Real World Research and Chronic Disease Forum

2022year8month span>6Day,Servierthe company hosted by China HealthInformation and Health MedicalBig DataScholarshipAssociationCounty Area Grassroots Special Committee Association The First ViewSeetrueWorld Research and Chronic DiseasesForumwas grandly held in Hangzhou. This conferencetotal160A doctor came to the site to attend the meeting, and the online platform hits 12000times.

ChinaAcademy of EngineeringZhang YunAcademician, Nanjing Medical DepartmentThe First Affiliated Hospital of UniversityKongXiangProfessor Qing strong>with the First Affiliated Hospital of Zhejiang University of Traditional Chinese MedicineMao WeiProfessorjoint As the chairman of thismeeting, 28peoplefrom chronic diseases across the country Top experts in the field are betterdoing real-world researchand howfor China chronic diseasepatients are standardizedsystematizationsystemization Management shared, communicated and prospected to explore the real world researchhowbetter application span>Chronic disease management to improve the current chronic disease managementstatus,help to benefit more patients !

The launch ceremony of the first real world research forum on chronic diseases

p >

Professor Yuan Hong domestic width=”600″> Real-world research and real-world evidence (RWE) have developed rapidly in recent years. In the context of the era of big data, real-world research on chronic diseases has developed rapidly. Professor Yuan Hong from the Third Xiangya Hospital of Central South University first pointed out that the current research on clinical problems has gradually changed from hypothesis-based to data-driven. The big data-driven clinical research system includes three aspects: data platform, methodological platform and clinical problems. The data platforms mainly include environmental and public health databases, death databases, and hospital information system (HIS) data. The construction of the methodological platform includes meta-analysis, cohort study, molecular mapping model construction, etc. The clinical issues addressed include the epidemiological characteristics of cardiovascular disease, new risk factors and targets, and indicators of vascular aging. Professor Yuan further pointed out that data-driven related research on chronic diseases such as hypertension in the past five years involves chronic disease management problems such as chronic disease risk factor investigation, risk assessment and prediction model, vascular aging, and hospitalized patient management. achieved remarkable results. Professor Li Jing

Professor Li Jing from Fuwai Hospital, Chinese Academy of Medical Sciences shared the practice of real-world big data in hypertension management. This project is an early screening and comprehensive intervention project for people at high risk of cardiovascular disease, covering millions of community cohorts across the country. The results of its research suggest that we should ensure that diagnosed hypertensive patients receive effective and adequate treatment; clear blood pressure targets, regular follow-up, and monitoring Blood pressure and timely adjustment of drugs are effective measures to improve the control rate; isolated diastolic hypertension (IDH) is the most neglected type of hypertension, and early screening and timely diagnosis should be paid attention to in young people.

Professor Zhan SiyanSchool of Public Health, Peking University Professor Zhan Siyan pointed out that high-quality real-world evidence comes from good research design. A good research design considers data, methods, platforms and collaboration. Real-world data (RWD) is not perfect and needs governance. An appropriate RWD can be selected according to PICO and the authenticity of the algorithm can be evaluated. From RWD to RWE, bias and confounding are the enemy and need to be addressed through proper design and analysis to standardize the RWE methodology. In terms of platform, it is necessary to build a special disease cohort/population cohort; at the same time, multidisciplinary cooperation should be actively carried out. Professor Hong FuyuanProfessor Richard Donnelly

Real-world research is a key content of this year’s Vision Forum. Professor Richard Donnelly from the University of Nottingham, UK, discusses the advantages of real-world studies over randomized controlled studies (RCTs). He pointed out that although RCT is the “gold standard”, the inclusion/exclusion criteria are very strict and performed outside routine clinical practice; The results may not be replicable in daily practice, Trial populations are not representative of real-world practice. RWE utilizes real-world data with low cost and short duration (especially retrospective studies), and does not require special assessments of participation rates, intervention exposures, and monitoring, reflecting real-world usage.

Dr. Wang BinhuiConclusion

The first “Servier Real World Research and Chronic Disease Summit” was a complete success! In the future, Servier China will continue to devote itself to the field of chronic diseases, strengthen cooperation with experts, and provide more innovative solutions to benefit more patients!

Group photo of the first real-world research and chronic disease forum